clinical trial · NCT07450976
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·recruiting·n = 151
Biliary Tract CancerSHR-A1904 for Injection
brief summary
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
started
Mar 25, 2026
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Mar 31, 2026
official title
A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol